For insitro's target identification platform, how can we balance the desire for novel biological insights against the need for targets with established druggability?

Introduction

The challenge at hand is balancing novel biological insights against established druggability for insitro's target identification platform. This trade-off is crucial for advancing drug discovery while ensuring practical application. I'll analyze this problem through the lens of product strategy, user impact, technical feasibility, and business objectives.

Step 1

Clarifying Questions (3 minutes)

• Context: I'm assuming insitro's platform uses AI for drug target discovery. Could you confirm if this is correct and elaborate on the current success rate of identifying druggable targets?

Why it matters: Helps gauge the current performance baseline Expected answer: AI-driven with moderate success rate Impact: Higher success rate might favor established targets; lower rate could justify more novel exploration

• Business Context: Is the company's primary revenue model based on partnerships with pharma companies or developing its own drug pipeline?

Why it matters: Influences the balance between short-term results and long-term innovation Expected answer: Hybrid model with both partnerships and internal development Impact: Partnership focus might lean towards established targets; internal pipeline could allow more novel exploration

• User Impact: Who are the primary users of the platform - internal scientists, partner researchers, or both?

Why it matters: Different users may have varying preferences for novelty vs. established targets Expected answer: Mix of internal and external users Impact: Would need to design a solution that caters to both user groups' needs

• Technical: What's the current capability of the platform in predicting druggability for novel targets?

Why it matters: Affects the risk associated with pursuing novel insights Expected answer: Moderate capability with ongoing improvements Impact: Higher capability could justify more focus on novel targets

• Resource: What's the current allocation of resources between novel target discovery and validation of established targets?

Why it matters: Indicates current strategic priorities and potential for shift Expected answer: 60% established, 40% novel Impact: Significant imbalance might suggest need for reallocation